A Novel Imidazopyridine Derivative Exhibits Anticancer Activity in Breast Cancer by Inhibiting Wnt/β‑catenin Signaling.
Liu-Jun HeDong-Lin YangHe-Ying ChenJiu-Hong HuangYa-Jun ZhangHong-Xia QinJuan-Li WangDian-Yong TangZhong-Zhu ChenPublished in: OncoTargets and therapy (2020)
C188 treatment resulted in the downregulation of cyclin D which led to cell cycle arrest at the G1 phase, and the inhibition of cell migration, indicating that C188 may be an effective novel therapeutic candidate as a potential treatment for human breast cancer.